NewLink in $1 bln deal with Roche to develop cancer drug
October 20, 2014 at 07:35 AM EDT
Oct 20 (Reuters) - NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.
